The USFDA has warned Cipla about its manufacturing processes at its Pithampur factory

20 Nov 2023 , 12:29 PM

The US Food and Drug Administration (US FDA) has issued a warning letter to Cipla, a prominent player in the pharmaceutical industry, regarding the routine current Good Manufacturing Practices (cGMP) inspection that was carried out at its Pithampur manufacturing plant from February 6 to February 17, 2023.

This warning letter outlines infractions pertaining to procedures or controls used at the facility that do not follow the specified cGMP rules and offers instructions for making the required corrections.

The company notified the exchanges that it will reply to the Warning Letter within the allotted time frames and that it will collaborate closely with the US FDA to address the issues in a comprehensive and timely manner in order to ensure sustained compliance. ‘We uphold quality and compliance with utmost importance and remain committed to be compliant with cGMP quality standards,’ added the statement.

For feedback and suggestions, write to us at [e-mail]